Corneal NeovascularizationNCT00515684
Corneal Thinning During Topical Bevacizumab Therapy
A study testing bevacizumab (Avastin) in people with Corneal Neovascularization, run by Yonsei University at 1 site in South Korea.
Trial summary
The purpose of this study is to determine whether topical bevacizumab is safe or not when used in corneal neovascularization for long term period. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Corneal Neovascularization
- What is being tested?
- bevacizumab (Avastin)
- How many people
- 0 participants
- Where
- 1 siteSouth Korea
- Study dates
- May 2007to Dec 2008
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Who may be able to join
- clinical diagnosis of corneal neovascularization
- must be able to apply eyedrop
Who cannot join
- have active keratitis
Trial locations and contacts
1 site in 1 country.
About this study
The purpose of this study is to determine whether topical bevacizumab is safe or not when used in corneal neovascularization for long term period.
- Conditions
- Corneal Neovascularization
- Being tested
- bevacizumab (Avastin)
- Medical subject headings
- Corneal Neovascularization
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
bevacizumab (Avastin)Drug
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2007 (estimated)
- Study startMay 2007
- Primary completionDec 2008
- Study completionDec 2008
Why it stopped: Side effect can increase the risk of the research
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Corneal NeovascularizationStudies of the same condition, open and under way.
- More trials run by Yonsei UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Yonsei University
- Sponsor type
- University, hospital or other
- Investigators
- Sang Woo Kim, M.D., Principal investigator, Severance hospital, Seoul , Korea
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00515684
- Sponsor's protocol ID
- 4-2006-0234
- Status last verified
- Apr 2015
- First submitted
- 13 Aug 2007
- Last updated
- 1 May 2015
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Corneal Thinning During Topical Bevacizumab Therapy
- ClinicalTrials.gov ID
- NCT00515684
- Acronym / sponsor ID
- 4-2006-0234
- Conditions
- Corneal Neovascularization
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Side effect can increase the risk of the research
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Yonsei UniversityUniversity, hospital or other
- Study start
- May 2007
- Primary completion
- Dec 2008 (actual)
- Study completion
- Dec 2008 (actual)
- First posted
- 14 Aug 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether topical bevacizumab is safe or not when used in corneal neovascularization for long term period.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (2 listed)
- clinical diagnosis of corneal neovascularization
- must be able to apply eyedrop
Key exclusion criteria (1 listed)
- have active keratitis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| bevacizumab (Avastin) | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2015.
Related trials for Corneal Neovascularization
RecruitingPhase 2/3
Corneal Crosslinking for Treatment of Corneal Neovascularization
Corneal Neovascularization
Recruiting
Fine-needle Diathermy Combined With Subconjunctival Bevacizumab for Corneal Neovascularization
Corneal Neovascularisation
RecruitingPhase 1/2
Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization.
Herpes Simplex Keratitis, Corneal Neovascularization
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sang Woo Kim, M.D. principal investigator
Severance hospital, Seoul , Korea
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing bevacizumab (Avastin) in people with Corneal Neovascularization, run by Yonsei University at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 1 May 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2015.